沙特食品药品监督管理局（FDA）已对ImmunityBio, Inc.（纳斯达克代码：IBRX）旗下免疫疗法药物Anktiva®授予加速审批资格，批准其与检查点抑制剂联合用于治疗转移性非小细胞肺癌（NSCLC）患者。此项决定标志着该创新组合疗法在沙特阿拉伯监管流程中的关键进展，为晚期肺癌患者提供了新的潜在治疗选择。
沙特食品药品监督管理局（FDA）已对ImmunityBio, Inc.（纳斯达克代码：IBRX）旗下免疫疗法药物Anktiva®授予加速审批资格，批准其与检查点抑制剂联合用于治疗转移性非小细胞肺癌（NSCLC）患者。此项决定标志着该创新组合疗法在沙特阿拉伯监管流程中的关键进展，为晚期肺癌患者提供了新的潜在治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.